flutamide / Generic mfg. - LARVOL DELTA

Short-Term Androgen Deprivation Therapy and High-Dose Radiotherapy in Intermediate- and High-Risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase III Trial (ASTRO 2024) - "RT dose was 80 Gy in both arms and STADT was monthly triptorelin and daily flutamide for a total duration of 4 months, starting 2 months before irradiation. STADT improves disease-free survival in intermediate and high-risk prostate cancer patients receiving high dose (80 Gy) RT, without any deterioration in the safety profile."

Clinical • Late-breaking abstract • P3 data • Gastrointestinal Disorder • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. (PubMed, Eur Urol) - "STADT is a well-tolerated and effective strategy that can enhance oncological outcomes when combined with high-dose RT, particularly for patients with intermediate- or high-risk prostate cancer."

Journal • P3 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Sexual dimorphism in keratoconus: transcriptomic and hormonal mechanisms underlying stromal remodelling. (PubMed, Eye Vis (Lond)) - "KC exhibited sex-biased molecular programs consistent with androgen-driven and oestrogen-deficiency-related stromal remodelling. These findings elucidate hormone-driven mechanisms underlying KC and suggest that sex-associated hormonal regulation could inform future personalised therapeutic strategies."

Journal • Ophthalmology • MIR942

Polycystic Ovarian Syndrome - exploring the therapeutic and biomedical insights into the role of Silver nanoparticles. (PubMed, J Steroid Biochem Mol Biol) - "Conventional medicines, such as metformin, clomiphene citrate, letrozole, flutamide, and rosiglitazone, can regulate menstrual irregularities, improve ovulation, reduce insulin resistance, and decrease androgen levels, but may also cause various side effects. The review includes evidence from insulin, inflammation, oxidative processes, neuroendocrine factors and cystogenic pathways to combine and provide an overview. The review also discusses how to approach toxicity, especially dose-dependent, and the reproductive safety of AgNPs and their translational limitations to define the boundaries of AgNPs in the treatment of PCOS."

Journal • Review • Endocrine Disorders • Inflammation • Polycystic Ovary Syndrome • Women's Health

Overview of the Efficacy and Safety of Topical Hormonal Therapies for the Treatment of Acne Vulgaris: A Narrative Review. (PubMed, J Clin Aesthet Dermatol) - "Available evidence supports the use of clascoterone cream 1% and suggests potential benefits and limitations of topical spironolactone in patients with AV; however, for topical spironolactone, pharmacokinetic studies and large-scale RCTs are needed to better characterize both efficacy and safety profiles."

Journal • Review • Acne Vulgaris • Dermatology

Inflammasome Activation and Idiosyncratic Drug-induced Liver Injury: Fusion Study of Basic and Real-world Data (PubMed, Yakugaku Zasshi) - "We have shown that the metabolites of drugs such as acetaminophen, flutamide, and bicartamide activate the inflammasome response in APCs...In this review, we present the findings of our previous studies on the pathogenesis of IDILI, including those on reactive metabolites and immune activation. We also present the results of the real-world data analysis which validated the pathogenic mechanism of IDILI that was previously elucidated through basic research, showcasing our efforts to integrate basic and clinical research."

Journal • Real-world evidence • Review • Hepatology • Liver Failure • Oncology

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. (PubMed, Lancet Oncol) - P3 | "The addition of enzalutamide to standard of care showed sustained improvement in overall survival for patients with metastatic hormone-sensitive prostate cancer and should be considered as a treatment option for eligible patients."

Journal • Metastases • P3 data • Alzheimer's Disease • Cardiovascular • CNS Disorders • Fatigue • Febrile Neutropenia • Genito-urinary Cancer • Hematological Disorders • Hypertension • Neutropenia • Oncology • Prostate Cancer • Solid Tumor

Male Rat Model of Chemical Androgen Deprivation and Estrogenization from the Perspective of Anthropometric, Histological, and Biochemical Parameters. (PubMed, Medicina (Kaunas)) - "Materials and Young adult Wistar rats were divided into nine groups: intact control (IC), control vehicle (CV), cyproterone acetate-treated (CA), flutamide-treated (F), control sesame oil (CO), estradiol valerate-treated (E), combined control (CC), flutamide + estradiol valerate (F + E), and cyproterone acetate + estradiol valerate (CA + E)-treated groups. Regarding biochemical parameters, androgen deprivation and/or estrogenization caused marked changes in serum triglyceride, LDL (low-density lipoproteins), ALP (alkaline phosphatase), AST (aspartate aminotransferase), ALT (alanine aminotransferase), Bil-T (bilirubin), creatinine, and urea levels. Given the importance of these therapies in clinical practice, providing a model based on the evaluated parameters offers a solid platform for future research."

Journal • Preclinical • Dyslipidemia • Fibrosis • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Drug repurposing to combat multidrug-resistant hookworm. (PubMed, Biol Open) - "Flutamide exhibited a concentration-dependent inhibition of egg hatching and arrested larval development in MADR hookworm. These findings underscore the translational value of drug repurposing to accelerate therapeutic discovery against MADR helminths."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Effect of Testosterone on Maintenance of Morphine-induced Conditioned Place Preference: Androgen and μ-opioid Receptor Gene Expressions in PFC and NAc of Rats. (PubMed, Clin Psychopharmacol Neurosci) - "Testosterone (androgen receptor [AR] agonist, 2.5 mg/kg; i.m.) or flutamide (AR antagonist 10 mg/kg, i.m.) were administered in subsequent extinction period. This result could be due to the changes in the expression of opioid and androgenic receptors in PFC and NAc. This study confirms the crucial role of androgen system in modulating drug reward."

Journal • Preclinical • AR

Exploring the interplay of electron density distribution and electrostatic potential in the interaction of nilutamide and flutamide with androgen receptors using quantum crystallography. (PubMed, RSC Adv) - "The results of the high-resolution X-ray experiment and the advanced computational charge density study of NIL and FLU allows us to understand drug binding and is useful to relate their differing biological effects and toxicities at the electronic level. This information pertains to the design of a new potential androgen inhibitor with improved binding affinity and fewer side effects."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • AR

Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer. (PubMed, Oncologist) - P2 | "The combination of flutamide+PROSTVAC did not improve outcomes in men with nmCRPC compared with flutamide alone. (ClinicalTrials.gov Identifier: NCT00450463)."

Clinical • Journal • Metastases • Genito-urinary Cancer • Immune Modulation • Oncology • Prostate Cancer • Solid Tumor

Mitochondrial AR overactivation coupled with uterine decidual mitochondrial defects in PCOS-associated pregnancy loss. (PubMed, J Endocrinol) - "In addition, flutamide normalized uterine Ar mRNA and mitochondrial AR protein expression; inner membrane mitochondrial protein (Immt), ras homolog enriched in brain protein (Rheb), and Mrp7 mRNA expression; and the Parkin: PTEM-induced putative kinase 1 (Pink1) ratio and restored total nicotinamide adenine dinucleotide (NAD) and ATP contents. Collectively, this work identifies mitochondrial AR in the uterus and implicates hyperandrogenism-induced, AR-dependent mitochondrial dysfunction in decidual stromal cells as a key mechanism underlying pregnancy loss in PCOS."

Journal • Metabolic Disorders • Polycystic Ovary Syndrome • AR • CFTR • RAS • RHEB

Non-Hormonal Pharmacological Interventions in Adolescent Polycystic Ovary Syndrome (PCOS): A Systematic Review. (PubMed, J Pediatr Adolesc Gynecol) - "Metformin appears to have some benefits for adolescents with PCOS, offering some metabolic and menstrual benefits based on a small number of observational studies and small RCTs. SPIOMET and flutamide & metformin show superior, multi-domain efficacy but should be studied in larger RCTs. Critical gaps include adolescent-specific GLP-1RA data and standardised outcome measures to guide optimal non-hormonal strategies."

Journal • Review • Metabolic Disorders • Polycystic Ovary Syndrome • GDF15

Retraction Note: The effect of Ganoderma lucidum polysaccharide extract on sensitizing prostate cancer cells to flutamide and docetaxel: an in vitro study. (PubMed, Sci Rep) - No abstract available

Journal • Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Sex- and Lineage-Dependent Transgenerational Effects of Vinclozolin and Flutamide on Rat Development and Behavior. (PubMed, J Endocr Soc) - "More behavioral effects of VIN emerged at the F3 generation's paternal lineage compared to the F1 generation. Overall, this study provides more detailed insight into the transgenerational effects of a high dose of VIN exposure and suggests future inquiry into the mechanisms of action of the EDC, specifically as it pertains to its differences from FLUT and its differing effects on lineage, sex, and generation."

Journal • Preclinical • Mood Disorders • Psychiatry

NRG-GU002: Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery (clinicaltrials.gov) - P2/3 | N=612 | Completed | Sponsor: NRG Oncology | Active, not recruiting ➔ Completed | Trial completion date: May 2026 ➔ Oct 2025 | Trial primary completion date: May 2026 ➔ Oct 2025

Trial completion • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Self-assembled xK1 rosette nanotube as a nanocarrier for chemotherapeutic drug molecules: a molecular dynamics study. (PubMed, RSC Adv) - "Chemotherapy is widely recognized as an effective treatment for various types of cancers, relying on chemotherapeutic drugs such as chlorambucil (CBL), camptothecin (CPT), doxorubicin (DOX), and flutamide (FLU) to inhibit cancer cell metastasis through their cytotoxic effects. Furthermore, MD simulations of the release mechanism revealed structural disassembly, validating the responsiveness of the systems under acidic conditions. The findings here offer insights into the viability of xK1 for targeted drug delivery, which warrants further experimental studies."

Journal • Alopecia • Infertility • Oncology • Pain • Sexual Disorders

Anti-androgenic compound Embelin ameliorates polycystic ovary syndrome by reversing the ovarian dysfunction and associated metabolic irregularities in 5α-DHT-induced PCOS rats. (PubMed, Fitoterapia) - "The anti-androgenic activity of the extracted Embelin was evaluated using the Yeast RIKILT Androgen Assay and compared against (i) 5α-dihydrotestosterone (5α-DHT), (ii) a commercially sourced Embelin standard, and (iii) flutamide, a known androgen receptor antagonist. Embelin treatment effectively reversed several hallmark features of PCOS, including ovarian dysfunction (e.g., hypo-progesteronemia, follicular cysts, and estrous cycle irregularities) as well as metabolic disturbances such as insulin resistance, weight gain, dyslipidaemia, and adipocyte hypertrophy. In conclusion, this is the first study to demonstrate the therapeutic potential of Embelin in ameliorating PCOS-related ovarian and metabolic dysfunctions."

Journal • Preclinical • Dyslipidemia • Metabolic Disorders • Polycystic Ovary Syndrome

Cyproterone acetate for hirsutism. (PubMed, Cochrane Database Syst Rev) - "There were some differences in clinical outcome between CPA and spironolactone, CPA and flutamide, and CPA and finasteride. There were no clinical differences between CPA and the other medical therapies, possibly because of small study size, lack of standardised assessment and objective determinants of improvement in many studies. There are insufficient data presented to compare the adverse effects of all the treatment options. Larger, carefully designed studies are needed to compare efficacy and safety profiles between the therapeutic options available."

Clinical • Journal • Review • Gynecology

Sex differences in microglia morphology and function across the lifespan are mediated by the early hormone environment. (PubMed, Brain Behav Immun) - "Testosterone treatment also resulted in greater transcriptomic changes in the aged hippocampus compared to flutamide treatment, especially in genes related to mitochondrial function and inflammation. These results indicate that (1) early hormone environment is critical for the induction of sex differences in microglial morphology and (2) sex differences in microglial morphology reverse during aging, and this reversal is also recapitulated with early hormone treatment."

Journal • Inflammation

Characteristics, treatment patterns and healthcare resource use of Finnish men with prostate cancer. (PubMed, BJUI Compass) - "In the mPC cohort, ADT (92%), radiotherapy (38%) and first-generation antiandrogens bicalutamide or flutamide (22%) were the most common first-year treatments. As expected, the disease burden seems to be higher among men with metastatic disease. The estimated high proportion of patients with mPC at or soon after diagnosis should be interpreted with caution."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Computational discovery of resiniferatoxin and euphol as potential androgen receptor inhibitors for prostate cancer therapy. (PubMed, Comput Biol Chem) - "This screening identified two leading compounds, Resiniferatoxin and Euphol, both demonstrated favorable binding poses and docking scores of -10 kcal/mol and -8.6 kcal/mol, respectively, surpassing Flutamide, the standard antiandrogen (-7.7 kcal/mol). Furthermore, a 100 ns molecular dynamics simulation showed that these two molecules formed stable complexes with AR, suggesting their potential utility as natural AR inhibitors in prostate cancer therapy. However, additional experimental studies are essential to validate their efficacy, elucidate their mechanisms of action, and assess their safety profiles, potentially paving the way for innovative plant-based treatments targeting AR-driven prostate cancer."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Pulp and paper mill industry effluent yields androgenic and anti-androgenic activity and leads to a reproduction arrest in fathead minnow. (PubMed, Environ Pollut) - "While ER activity was low (<0.01 ng/L EEQ (estrogen-equivalent)), AR and anti-AR activities were measured at ∼1.8 ng/L DHT-Eq (dihydrotestosterone equivalent) and at ∼209 μg/L FLU-Eq (flutamide equivalent), respectively...20 out of 150 chemical compounds were quantified, including bisphenol A and S - known EDCs, which yielded ∼500 and 2,000 μg/L, respectively. Overall, this study validates that the approach used can detect EDC activity in a pulp and paper mill effluent, which could help better understand their impacts in receiving aquatic ecosystems."

Journal • ER

Innovative Se-Flutamide Derivatives: Enhanced Activity Toward Androgen Receptor (AR)-Dependent and -Independent Prostate Cancer Cells. (PubMed, Arch Pharm (Weinheim)) - "Besides, it induced the G0/G1 cell cycle arrest. Altogether, it could be concluded that this Se-flutamide analog could be a feasible and promising candidate for further development for the treatment of both AR-dependent and -independent prostate cancers."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • AR